

I hereby certify that this correspondence is being filed via  
EFS-Web with the United States Patent and Trademark Office  
on \_\_\_\_\_.

PATENT  
Attorney Docket No.: 057436-392276

ALSTON & BIRD LLP

By: \_\_\_\_\_  
ShengFeng Chen

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Yednock, Ted  
Vasquez, Nicki  
Bard, Frederique  
Seubert, Peter A.

Application No.: 10/544,093

Filed: August 1, 2005

For: ACTIVE IMMUNIZATION TO  
GENERATE ANTIBODIES TO  
SOLUBLE A-BETA

Customer No.: 00826

Confirmation No. 6443

Examiner: Gregory S. Emch

Technology Center/Art Unit: 1649

DECLARATION UNDER 37 CFR 1.132

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

1. I, Jack Steven Jacobsen, state as follows.
2. I am currently an independent pharmaceutical professional. From 2001 to 2009, I served as Associate Director for Neuroscience, Wyeth Research, Princeton, NJ 08543. Wyeth Research is a division of Wyeth. I understand that Wyeth is a co-assignee of the above-captioned application. A copy of my curriculum vitae is attached.
3. From 2001 to 2004, I and/or others acting under my supervision have performed experiments to test A $\beta$ 16-23. Here, I present experiments that show A $\beta$ 16-23 consistently generates an immune response and has activity in inhibiting cognitive decline but does not induce a T-cell response against A $\beta$  notwithstanding that it occurs in a region of A $\beta$  (residues 14-30) in which most T-cell epitopes are located. These results

provide evidence that A $\beta$ 16-23 is surprisingly advantageous for treatment or effecting prophylaxis of Alzheimer's disease. The details of these experiments are as follows.

4. In the first experiment, I studied the effect of active immunization with A $\beta$ 16-23 on contextual memory of the transgenic (Tg2576) mice. The transgenic (Tg2576) mice were heterozygous for the K670N/M671L amyloid precursor protein transgene and all transgenic genotypes were confirmed by PCR and all animals homozygous for the Retinal Degeneration (Rd) mutation were excluded. The background strain consisted of a C57Bl6 and 129SjL cross. Tg2576 mice exhibited cognitive deficits in contextual memory beginning at 14-16 weeks of age. Cognitive deficits were particularly prominent at 20 weeks of age and were maintained up to 65 weeks of age.

5. The testing apparatus for the experiment was as follows. Transgenic mice and wild-type littermate control mice were individually housed for at least 2 weeks prior to any testing and allowed *ad libitum* access to food and water. Contextual Fear Conditioning (CFC) Assay occurred in six 30 x 24 x 21cm operant chambers (Med Associates, Inc.) constructed from aluminum sidewalls and plexiglass ceiling, door and rear wall. Each chamber was equipped with a floor consisting of 36 stainless steel rods through which a foot shock could be administered. In addition, each chamber had 2 stimulus lights, one house light and a solenoid. Lighting, the footshock (US) and the solenoid (CS) were all controlled by a PC running MED-PC software. The chambers were located in a sound isolated room in the presence of red light.

6. I and/or others acting under my supervision conducted Contextual Fear Conditioning (CFC) assays according to the following protocol. Mice (n=8-12/genotype/treatment) were trained and tested on two consecutive days. The Training Phase consisted of placing the mice in the operant chambers, illuminating both the stimulus and houselights and allowing them to explore for 2 minutes. At the end of the two minutes, the auditory cue (2Hz clicking via the solenoid; CS) was presented for 15 seconds. The footshock (US; 1.5 mAmp) was administered for the final 2 seconds of the CS and co-terminated with the CS presentation. This procedure was repeated and 30 seconds after the second foot shock the mice were removed from the chambers and

returned to their home cages. Twenty hours after training, animals were returned to the chambers in which they had previously been trained. Freezing behavior, in the same environment in which they had received the shock (“Context”), was then recorded by the experimenter using time sampling in 10 seconds bins for 5 minutes (30 sample points). Freezing was defined as the lack of movement except that required for respiration. At the end of the 5 minute Context test mice were returned to their homecages. Freezing in the Novel and Cue condition was collected after all of the mice had been tested in Context (~60 minutes after the initial Context test). The novel environment consisted of modifications of the operant chamber including an opaque plexiglass divider from the rear right corner to the front left, a plexiglass floor as well as decreased illumination (houselight only). Mice were placed in the Novel context and time sampling was used to collect freezing scores for 3 minutes (18 sample points). At the end of the 3 minutes, the auditory clicker (CS) was presented for 3 minutes during which freezing was again scored (18 sample points). Freezing scores for each animal were converted to percent freezing for each portion of the test. Memory for the context (Contextual memory) for each animal was obtained by subtracting freezing score in the novel condition (a measure of basal activity) from that observed in the context.

7. The treatment regime for experiment 1 is as follows. Wild-type and Tg2576 mice were administered (1) adjuvant RC529SE alone, (2) CRM<sub>197</sub> (“CRM”) and adjuvant RC529SE, (3) 30 µg Aβ16-23 antigen conjugated with CRM, and adjuvant RC529SE, (4) 50 µg Aβ16-23 antigen conjugated with CRM, and adjuvant RC529SE, or (5) 266 monoclonal antibody and adjuvant RC529SE by intraperitoneal injection at 47 days prior to the training phase of the CFC and followed by booster doses of the same amount at 19 and 7 days prior to the training phase of the CFC. The days described correspond to mice age at 13, 17 and 19 weeks. The training phase of CFC was conducted at day 47, *i.e.*, in 20 week old mice.

8. The results show that Tg2576 mice displayed prominent and significant cognitive deficit reversal when administered Aβ16-23 antigen conjugated with CRM and adjuvant RC529SE. This agent was an effective treatment at both doses tested (30 or 5

μg) (*see* Fig. 1). The adjuvant-only control (*i.e.*, no treatment) Tg2576 mice displayed a significant deficit in contextual-dependent memory (*i.e.* a significant memory impairment status) in comparison with wild-type mice (Fig. 1). As a positive control, monoclonal antibody 266 caused a significant improvement in contextual memory (*i.e.* significant memory deficit reversal) of Tg2576 mice relative to control treatments, and no significant memory impairment with respect to wild-type mice.

9. In the second experiment, I studied the effect of active immunization with Aβ16-23 on contextual memory of the pre-plaque-forming PSAPP transgenic mice. The transgenic PSAPP mice over-expressed mutant forms of both APP (e.g. Swedish-type mutant APP (hAPP<sub>swe</sub>)) and PSEN-1 (e.g. mutant human PS1.sub.M146L) (*see* Holcomb et al., (1998) Nat. Med, 4: 97-110). PSAPP mice exhibited age-related development of amyloid plaques that is similar to that observed in Alzheimer's disease. Deposition of Aβ in the frontal cortex and hippocampus of PSAPP mice as early as 3 months of age progresses to cover substantial portions of these areas of the brain at 12 months. Prominent contextual memory deficit and dense accumulation of plaque were particularly prominent at 20 weeks of age.

10. The testing apparatus for the second experiment was the same as described in paragraph (5).

11. I and/or others acting under my supervision conducted Contextual Fear Conditioning (CFC) assays for this experiment according to the protocol described in paragraph (6).

12. The treatment regime for experiment 2 is as follows. Wild-type and PSAPP mice were administered with (1) adjuvant RC529SE alone, (2) CRM and adjuvant RC529SE or (3) Aβ16-23 antigen conjugated with CRM and adjuvant RC529SE by intraperitoneal injection at 47 weeks prior to the training phase of the CFC and followed by booster doses of the same amount at 46, 43, 38, 34, 23, 14, 9, 4 weeks and 1 week prior to the training phase of the CFC. The PSAPP mice for the experiment were

approximately 8-10 weeks of age during the first immunization. The training phase of CFC was conducted at week 47, *i.e.*, in approximately 50-57 week old mice.

13. The results show that cognitive deficits were significantly inhibited when A $\beta$ 16-23 antigen conjugated with CRM, and adjuvant RC529SE was administered to PSAPP mice (see Fig. 2). The adjuvant-only adjuvant-only control (*i.e.*, no treatment) and the CRM and adjuvant RC529SE Tg2576 mice displayed a significant deficit in contextual-dependent memory in comparison with wild-type mice (Fig. 2).

14. In the third experiment, I studied the effect of active immunization with A $\beta$ 16-23 on contextual memory of the plaque-bearing PSAPP transgenic mice. The PSAPP transgenic mice is as described in paragraph (9).

15. The testing apparatus for the third experiment was the same as described in paragraph (5).

16. I and/or others acting under my supervision conducted Contextual Fear Conditioning (CFC) assays for this experiment according to the protocol described in paragraph (6).

17. The treatment regime for the third experiment is as follows. Wild-type and PSAPP mice were administered (1) adjuvant RC529SE alone, (2) CRM and adjuvant RC529SE, (3) A $\beta$ 16-23 antigen conjugated with CRM, and adjuvant RC529SE or (4) 266 monoclonal antibody and adjuvant RC529SE by intraperitoneal injection at 25 weeks prior to the training phase of the CFC and followed by booster doses of the same amount at 21, 16, 11, 7 days and 1 day prior to the training phase of the CFC. The PSAPP mice for the experiment were approximately 12-13 months of age during the first immunization. The training phase of CFC was conducted at week 25, *i.e.*, in approximately 18-19 month old mice.

18. The results show that plaque bearing PSAPP mice displayed significant improvement in contextual memory (*i.e.* significant cognitive deficit reversal) when administered A $\beta$ 16-23 antigen conjugated with CRM, and adjuvant RC529SE (*see* Fig.

3). The adjuvant-only (*i.e.*, no treatment) and the CRM and adjuvant RC529SE treated PSAPP mice displayed a significant deficit in contextual-dependent memory in comparison with wild-type mice (Fig. 3). As a positive control, monoclonal antibody 266 also caused a significant improvement in contextual memory of PSAPP mice relative to control treatments.

19. In the fourth experiment, I studied the effect of active immunization with A $\beta$ 16-23 on reduction of amyloid plaque formation in PSAPP transgenic mice. The PSAPP transgenic mice for the fourth experiment was the same as described in paragraph (9). In this study, there were 7 groups of ~8-12 week old, Male, PSAPP mice, with approximately 28 Heterzygous transgenic mice (HH) and 20 wild type non-transgenic littermates (WW) mice per group.

20. The immunizations and bleeding methods of PSAPP mice were as follows: Experimental group 1 was immunized with A $\beta$ 16-23 conjugated with CRM<sub>197</sub> and group 2 was immunized with CRM<sub>197</sub> alone, both on weeks 0, 4, 9, 14, 19 and 24. Group 3 was used as a negative control and was immunized with PBS on the above mentioned weeks. All mice in groups 1-3 were immunized via subcutaneous injection in the rump with a total volume of 200  $\mu$ l (100  $\mu$ l in 2 rump sites administered immediately following each other). Groups 1 and 2 were bled on weeks 5, 15 and 19 via tail nick and all groups were bled on week 27 via the retro-orbital route (non-terminal) or cardiac puncture (terminal). . Less than 10% of the mouse's blood volume was collected at each time point (excluding the terminal bleed on week 25). Isoflurane was used as an inhalant anesthetic during retro-orbital bleeding.

21. The histological, histopathological, and morphometry methods for the brains of PSAPP mice were as follows: The mice were sacrificed between 401 and 425 days after birth. The brain of each PSAPP mouse was removed at necropsy, fixed by immersion in 10% neutral buffered formalin, and trimmed by transverse cuts into four pieces. All four pieces were placed in one tissue cassette identified with the animal number, and the tissue in this cassette was processed into paraffin wax using routine histological methods. Three serial microscopic sections of each brain were produced, and

one was stained with each of the following stains: (i). Hematoxylin and eosin for microscopic findings and microscopically-visible plaques (HE) and (ii). Thioflavin-S-stain for amyloid plaques (Thioflavin). A board-certified veterinary pathologist blinded as to treatment and group evaluated all sections microscopically. HE sections were evaluated for findings, and for microscopically-visible plaques (defined as hyaline acellular parenchymal deposits). The number of microscopically-visible plaques in each HE-stained section was quantified by manually counting the number present in one randomly selected field of view in the CA3 of the hippocampus using a 10x microscope objective. Thioflavin sections were evaluated for amyloid-bearing plaques, defined as foci with gold fluorescence when viewed under ultraviolet epifluorescent light. The number of thioflavin-S-positive amyloid-bearing plaques in each Thioflavin-stained section was quantified by manually counting the number present in one randomly selected field of view in the CA3 of the hippocampus. Thioflavin sections were further evaluated for amyloid burden by capturing one photographic image (SNAP image tiff file) of one randomly selected field of view of the CA3 zone of the hippocampus of the brain of each mouse. Morphometry images were captured using ultraviolet epifluorescent light, a 10x microscope objective, a digital camera (Zeiss Axiocam HRc, Zeiss, Inc.), and the camera's matching software (Zeiss Axiovision, Zeiss, Inc.). Each SNAP image tiff file was analyzed individually, in a blinded fashion without knowledge of treatment or group, using Image Pro Plus 5.1 as follows: A. Each image was opened; The number of gold pixels in each image was quantified using the -> Count/Size function of Image Pro Plus 5.1 (MediaCybernetics, Inc., Silver Spring, MD) using the following settings for automated counts and measurements:

Area (range 500-1e+007)  
% area (Per Area; range 0-1)  
Intensity range selection= manual  
Ranges: Histogram based RGB (R=21/255; G=0/255; B=0/255)

Resulting raw data for each image (Raw unmodified data- no deselection) was exported to a Microsoft Excel spreadsheet. Group means for all findings and counts were calculated directly by Microsoft Excel.

22. The results show that immunization of young, pre-plaque-bearing PSAPP mice with A $\beta$ 16-23 antigen conjugated with CRM<sub>197</sub> inhibited amyloid plaque formation compared with immunization with CRM<sub>197</sub> alone or no immunization treatment (the "no Txt" bars) (*see* Figs. 4A and 4B).

23. In the fifth experiment, I studied the effect of active immunization with A $\beta$ 16-23 on induction of T-cell reactivity. In this study, 6-8 week old female, Balb/c mice (5 mice per group) were immunized with various A $\beta$  central epitope peptides conjugated to CRM<sub>197</sub> plus adjuvant RC529-SE as outlined in Table 1. Positive control animals were immunized with A $\beta$ 1-7 conjugated to CRM<sub>197</sub> plus adjuvant RC529-SE. Mice injected with PBS served as negative controls. Animals were immunized subcutaneously (total volume of 200  $\mu$ l) on weeks 0, 4, and 12 and bled on weeks 6, 12 and 13. On week 13 spleens were removed for analysis of cell-mediated immune (CMI) responses.

Table 1: Treatment and Number of Animals in each Group

Group #	A $\beta$ Central Epitopes Peptides Conjugated to CRM <sub>197</sub>	Immunization Schedule (Week)	Bleed /Harvest Schedule (Week)
1	(A $\beta$ 17-24-C) LVFFAEDVC + RC529-SE	0, 4, 12	6, 12, 13
2	(A $\beta$ 16-23-C) KLVFFAEDC + RC529-SE	0, 4, 12	6, 12, 13
3	(A $\beta$ 18-25-C) VFFAEDVGC + RC529-SE	0, 4, 12	6, 12, 13
4	(A $\beta$ C-17-24) CLVFFAEDV + RC529-SE	0, 4, 12	6, 12, 13
5	(A $\beta$ C-16-23) CKLVFFAED + RC529-SE	0, 4, 12	6, 12, 13
6	(A $\beta$ C-18-25) CVFFAEDVG + RC529-SE	0, 4, 12	6, 12, 13
7	(A $\beta$ 18-24-C) VFFAEDVC + RC529-SE	0, 4, 12	6, 12, 13
8	(A $\beta$ 17-23-C) LVFFAEDC + RC529-SE	0, 4, 12	6, 12, 13
9	(A $\beta$ 1-7-C) DAEFRHD + RC529-SE	0, 4, 12	6, 12, 13
10	PBS	0, 4, 12	6, 12, 13

24. The procedures for in vitro stimuli for ELISPOT assays were as follows: A $\beta$ 1-42 peptides were synthesized by using the concept of Solid Phase Peptide Synthesis (SPPS) utilizing 9-fluorenylmethoxy-carbonyl (Fmoc) chemistry. Peptide purity was determined by using HPLC and mass spectrophotometry analysis. Stock peptides were made in concentrations of 10 to 20 mg/mL in 100% DMSO, aliquoted, and kept frozen at



-20°C. A $\beta$ 1-42 peptides employed in the ELISPOT assays were used at equal molar concentrations (2  $\mu$ M/well). A $\beta$ 1-42 peptides used in this study were obtained from New England Peptide (Gardner, MA).

25. The procedures for enzyme-linked immunosorbent spot (ELISPOT) assay for the detection of IFN- $\gamma$  secreting cells were as follows: Enzyme-Linked Immunosorbent Spot (ELISPOT) Assay is a common method for monitoring immune responses in humans and animals. ELISPOT assays were originally developed to enumerate B cells secreting antigen-specific antibodies, and have subsequently been adapted for various tasks, especially the identification and enumeration of cytokine-producing cells at the single cell level. In brief, at appropriate conditions the ELISPOT assay allows visualization of the secretory product of individual activated or responding cells. Each spot that develops in the assay represents a single reactive cell. Thus, the ELISPOT assay provides both qualitative (type of immune protein) and quantitative (number of responding cells) information. ELISPOT assays were conducted to enumerate spleen cells secreting IFN- $\gamma$  after a 20- to 24-hour *in vitro* incubation with the stimuli, human A $\beta$ 1-42, CRM<sub>197</sub> (positive control) and media (negative control). IFN- $\gamma$  belongs to a class of small (15–28 kD) protein and glycoprotein cytokines (15–28 kD) produced by T cells, fibroblasts, and other cells in response to viral infection and other biologic and synthetic stimuli. IFN- $\gamma$  binds to specific receptors on cell membranes. Their effects include inducing enzymes, suppressing cell proliferation, enhancing the phagocytic activity of macrophages, and augmenting the cytotoxic activity of T lymphocytes. IFN- $\gamma$  is a good indicator for the measurement of T-cell response. Kits containing pre-coated plates, assay reagents, and buffers were obtained from BD Biosciences (San Diego, CA). All methods were carried out according to manufacture instructions. All ELISPOT plates were scanned and analyzed using the ImmunoSpot® Series 1 Analyzer (Cellular Technology Ltd.; Cleveland, OH). The frequency of Spot Forming Cells (SFC) was estimated from the number of spots in the wells, and is expressed as SFC/10<sup>6</sup> cells per well. A positive response was defined as having at least twice the number of SFC of that of the non-stimulus media control and having >50

SFC/ $10^6$  cells after media subtraction. Media wells with a background of  $>120$  SFC/ $10^6$  cells were discarded and not included in the analysis.

26. Table 2 represents the ELISPOT assay responses for spleen cells secreting IFN- $\gamma$  using the standard criteria as previously described. Mice immunized with central epitope A $\beta$  conjugates including A $\beta$ 16-23 (group 2, shaded) did not mount any A $\beta$  specific IFN- $\gamma$  responses above background levels (media control). All groups displayed positive in vitro responses to positive control CRM<sub>197</sub> except the PBS control (group 10) which did not mount a response to CRM<sub>197</sub>.

Table 2: IFN- $\gamma$  ELISPOT Assay Results

<i>In vitro</i> Stimuli	Group 1	Group 2	Group 3	Group 4	Group 5	Group 6	Group 7	Group 8	Group 9	Group 10
	A $\beta$ 17- 24-C	A $\beta$ 16- 23-C	A $\beta$ 18- 25-C	A $\beta$ C-17- 24	A $\beta$ C-16- 23	A $\beta$ C-18- 25	A $\beta$ 18- 24-C	A $\beta$ 17- 23-C	A $\beta$ 1-7- C	PBS
A $\beta$ 1-42	2	2	0	0	0	3	0	2	0	0
CRM <sub>197</sub>	118	280	183	148	277	382	467	232	92	0
Media	0	0	0	2	2	0	2	0	2	5

Values represent SFC /  $10^6$  spleen cells (Media background has been subtracted is displayed for reference only)

27. In the sixth experiment, I studied the binding of the antisera resulting from immunization with A $\beta$ 16-23 to A $\beta$  oligomers.

28. Polyclonal anti-A $\beta$  antibodies were prepared as follows: Anti-A $\beta$  polyclonal antibodies were prepared from blood collected from female balb/c mice that have been immunized with A $\beta$ 16-23 conjugated with CRM<sub>197</sub> plus either adjuvant QS-21 or 529SE, on weeks 0, 4 and 8 via subcutaneous route. Samples were collected via retro-orbital bleeds on weeks 2, 6 and 10 and animals were euthanized by CO<sub>2</sub> inhalation after the week 10 bleed. Serum was prepared and the sera were pooled. The antibody fraction was purified using two sequential rounds of precipitation with 50% saturated ammonium sulfate. The final precipitate was dialyzed against PBS and tested for endotoxin. The level of endotoxin was less than 1 endotoxin units/mg (EU/mg).

29. Synthetic A $\beta$  Oligomers were prepared as follows: The A $\beta$  oligomers and monomers present in an A $\beta$  preparation can be determined or visualized by a wide variety of techniques such as immunoprecipitation and Western blot analysis. A $\beta$  oligomers have molecular weights of, for example, about 8 kDa, about 12 kDa, about 16 kDa or about 20 kDa for trimers, tetramers or pentamers, respectively. A $\beta$  oligomers and monomers can consist of any full length A $\beta$  peptide, for example, A $\beta$ 1-42 or A $\beta$ 1-40, or combinations thereof. Preparation of synthetic A $\beta$  oligomers can be prepared by dissolving lyophilized A $\beta$ 1-42 peptides in a solvent to de-aggregate the peptides and produce a solution of substantially unaggregated A $\beta$  peptides. The A $\beta$  peptides are then recovered from the solution and incubated in a culture media to produce a preparation of synthetic A $\beta$  oligomers. The detailed protocol for the preparation of synthetic A $\beta$  oligomers is as follows. Lyophilized A $\beta$ 1-42 peptide was dissolved in 100% hexafluoroisopropanol (HFIP) to a final concentration of 100 $\mu$ M and separated into aliquots in microfuge tubes, permitting the peptide to assume a more uniform, unaggregated conformation. HFIP has been shown to break down  $\beta$ -sheet structure, disrupt hydrophobic forces in aggregated amyloid preparations, and promote  $\alpha$ -helical secondary structure. The HFIP was removed by both evaporation for 24 hrs in a chemical hood and lyophilization, to remove residual HFIP, and to yield an A $\beta$  peptide residue. The A $\beta$  peptide residue was stored desiccated at  $-20^{\circ}\text{C}$  for later use in preparing the aggregated A $\beta$  preparation or used immediately. To use the peptide, the A $\beta$  peptide was resuspended in dimethyl sulfoxide (DMSO) and added to Ham's F-12 (phenol red free) culture media to bring the peptide to a final concentration of 100 $\mu$ M. The resultant solution was then incubated at  $4^{\circ}\text{C}$  for 24 hrs to produce the A $\beta$  preparation. An A $\beta$  preparation, as prepared aforementioned, was treated with peroxynitrite in the presence of sodium hydroxide (NaOH). Peroxynitrite crosslinks tyrosines (*i.e.* A $\beta$  contains one tyrosine at position 10) and is predicted to stabilize the preparation.

30. The procedures for preparing SDS-PAGE gels for western blotting were as follows: Samples of A $\beta$  preparations were diluted in sample buffer ( $\sim 1$ -5 $\mu$ g per lane) and separated by SDS-PAGE on a 12% NuPAGE gel. The protein was transferred to

nitrocellulose membranes, the membranes were microwaved in PBS for 2 minutes, allowed to soak in the hot PBS for 3.5 minutes, and then microwaved again for 5 minutes. The membranes were blocked overnight at 4°C. in blocking buffer (LiCor; Odyssey Blocking Buffer). Membranes were incubated with the primary antibody diluted, as indicated in Fig. 5, in Blocking Buffer + 0.1% Tween 20, overnight at room temperature. The primary antibodies are 6E10 (binds to eptiopes within A $\beta$ 6-10), 3D6 (binds to eptiopes within A $\beta$ 1-5), 266 (binds to eptiopes within A $\beta$ 13-28), TY 11/15 (an unrelated IgG1 antibody) and mouse anti-sera collected from immunization of (i) A $\beta$ 16-23 conjugated with CRM<sub>197</sub> plus the adjuvant QS-21 and (ii) A $\beta$ 16-23 conjugated with CRM<sub>197</sub> plus the adjuvant 529SE. After washing membranes in 4 x 5 minutes in PBS + 0.1% Tween 20, membranes were incubated with secondary antibody Alexa 680 anti-mouse IgG. Membranes were washed 4 x 5 minutes in PBS + 0.1% Tween 20 and imaged in Licor's Odyssey Infrared Imaging System. Molecular mass was estimated by Licor's molecular weight markers.

31. The results show that the mouse monoclonal antibodies, 6E10, 3D6, and 266, used as positive controls here, recognized the soluble A $\beta$ 1-42 monomer (lower band) as well as higher-ordered oligomeric A $\beta$  species (*i.e.* trimer, tetramer) (Figure 5). The irrelevant antisera TY 11/15 served as a negative control and displayed little to no reactivity to A $\beta$ . In contrast, the antisera resulting from immunization with A $\beta$ 16-23 conjugated with CRM197 plus either adjuvant QS21 or 529SE reacted with both monomer and higher-ordered oligomeric A $\beta$  species, with stronger reactivity being displayed by those treated with QS21 compared to those of 529SE (1/5000 dilution resulted in greater intensity bands for the former sample versus latter sample at the same dilution), which is consistent with the calculated average titer (*i.e.* QS21=28,661 vs. 529SE=17,383). These data indicate that the mouse anti-sera to A $\beta$ 16-23 recognize both monomer and higher-ordered oligomeric A $\beta$  species.


32. I interpret these data as showing that A $\beta$ 16-23 is surprisingly advantageous for treatment or effecting prophylaxis of Alzheimer's disease.

33. All statements made of my own knowledge are true and statements made on information or belief are believed to be true. Further, these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under §1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.


Dated: \_\_\_\_\_

\_\_\_\_\_  
Jack Steven Jacobsen, Ph.D.


LEGAL02/32808730v1



**Fig. 1: Cognitive Studies. Reversal of cognitive deficits in Tg2576 mice through active immunotherapy with Aβ16-23/CRM<sub>197</sub>.**




**Fig. 2: Cognitive Studies. Prevention of cognitive deficits in PSAPP mice through active immunotherapy with A $\beta$ 16-23/CRM<sub>197</sub> plus adjuvant 529SE.**



**Fig. 3: Cognitive Studies. Treatment of cognitive deficits in PSAPP mice through active immunotherapy with Aβ<sub>16-23</sub>/CRM<sub>197</sub> plus adjuvant 529SE.**




## A Amyloid Plaque Density





Treatment	A $\beta$ 16-23/CRM <sub>197</sub>	CRM <sub>197</sub>	No Txt
Average	21.4	29.0	35.4
% Reduction	39.7	18.2	0
p Value (*M-W)	0.002	0.841	

## B Amyloid Burden



Treatment	A $\beta$ 16-23/CRM <sub>197</sub>	CRM <sub>197</sub>	No Txt
Average	83351	104507	129512
% Reduction	35.6	19.3	0
p Value (*M-W)	0.005	0.134	

**Fig. 4: Immunization of young PSAPP mice with A $\beta$ 16-23/CRM<sub>197</sub> reduces amyloid plaque formation.**



**Fig. 5: Aβ16-23/CRM<sub>197</sub> binds to Aβ oligomer**



## CURRICULUM VITAE

### Personal Data:

Name J. Steven Jacobsen, Ph.D.

Address Wyeth Research  
CN-8000  
Princeton, N.J. 08543  
Office: [732] 274-4238

Residence:  
229 Mulberry Road  
Ramsey, NJ. 07446  
Home: [201] 934-6777

### History:

Wyeth Research	07/1995 - Present
Princeton, NJ, USA	
Associate Director, Neurodegeneration Research	08/2001 - Present
Team Leader, Alzheimer's Disease Amyloid Programs	07/1995 - Present
Lederle Laboratories, American Cyanamid	05/1988 - 06/1995
Pearl River, NY, USA	
Team Leader, Alzheimer's Disease Program	07/1992 - 06/1995
Senior Scientist II, Alzheimer's Disease Program	01/1991 - 06/1992
Senior Scientist I, Alzheimer's Disease Program	12/1989 - 12/1990
Postdoctoral Scientist, Alzheimer's Disease Program	05/1988 - 11/1989

1995-Pres. Wyeth Neuroscience, Wyeth, Princeton, NJ.  
*Research Interests:* Disease-modifying strategies for the treatment of patients with Alzheimer's Disease.

1988-1995 Central Nervous System Biological Research Department, Medical Research Division, Lederle Laboratories, American Cyanamid Co., Pearl River, NY.  
*Research Interests:* Molecular mechanisms of Alzheimer's Disease: Expression and processing of Amyloid Precursor Proteins.  
1988-1989 Postdoctoral Scientist (Molecular Neurobiologist & Biochemist)  
1989-1995 Senior Research Scientist II (Molecular Neurobiologist)

1979-1983 Department of Dermatology, New York University School of Medicine, NYU Medical Center, NY, NY.  
*Research Interests:* Identification & purification of human melanoma-associated cell-surface proteins and the development of a vaccine for immunotherapy.  
1979-1980 Research Technician I  
1980-1981 Research Technician II  
1981-1982 Senior Research Technician

Education:

Graduate, Ph.D. in molecular genetics, Dr. M. Zafri Humayun, Dept. of Microbiology and Molecular Genetics, Graduate School of Biomedical Sciences, University of Medicine and Dentistry-New Jersey Medical School, Newark, NJ, 1983 - 1988.

Graduate, M.S. in biochemistry, Dr. John R. Keller, Department of Biology, Seton Hall University, South Orange, NJ, 1977 - 1979.

Undergraduate, B.S. in biology, Department of Biology, Seton Hall University, South Orange, NJ, 1974 - 1977.

Invited Lectures:

- 1989 "Molecular Mechanisms of Amyloid Peptide Precursor in Alzheimer's Disease." New Jersey Neuropsychopharmacology Society Annual Symposium, Princeton University, Princeton, NJ.
- 1989 "Alzheimer's Disease and the Molecular Mechanisms of Amyloid Peptide Precursor Expression." Graduate Biology Seminar Series, Department of Biology, Seton Hall University, South Orange, NJ.
- 1990 "Expression of Amyloid Peptide Precursor Expression and deposition of  $\beta$ -amyloid peptide in Alzheimer's Disease." Department of Biology, William Paterson College, Wayne, NJ.
- 1992 "Processing of  $\beta$ -amyloid peptide in Alzheimer's Disease." Department of Biology, William Paterson College, Wayne, NJ.
- 1993 "Molecular Mechanisms of Alzheimer's Disease: Therapeutic approaches to reduce the formation of  $\beta$ -amyloid peptide." Graduate Biology Seminar Series, Department of Biology, Seton Hall University, South Orange, NJ.
- 1994 "Alzheimer's Disease and  $\beta$ -amyloid peptide: Molecular Mechanisms to Block the Formation of  $\beta$ -Amyloid Peptide." Dept. of Molecular Biology and Molecular Genetics, University of Medicine and Dentistry-New Jersey Medical School, Newark, NJ.
- 1995 "Alzheimer's Disease and  $\beta$ -amyloid peptide: Molecular Mechanisms to Drug Discovery." Dept. of Environmental Medicine, NYU School of Medicine, Tuxedo, NY.
- 1995 "Therapeutic Strategies to Reduce Formation of  $\beta$ -amyloid peptide in

Alzheimer's Disease." Alzheimer's Disease: Latest Advances in Understanding and Treatment. Sponsored by IBC USA Conferences Inc., Waltham, Massachusetts.

- 1996 "Therapeutic Strategies to Reduce Formation of  $\beta$ -amyloid peptide in Alzheimer's Disease." Alzheimer's Disease: Advances in Diagnostics and Drug Development. Sponsored by IBC USA Conferences Inc., Oak Brook, Illinois.
- 1999 "Advances in Understanding the Molecular Mechanisms of Alzheimer's Disease." Depts. of Environmental Medicine and Biology, NYU School of Medicine, NY, NY.
- 2000 "Alzheimer's Disease: Development of Protease Inhibitors as A $\beta$ -Lowering Agents." American Home Products Corporation, Senior Managers Symposium, Baltimore, MD.
- 2001 "Alzheimer's Disease: Current and Emerging Therapeutic Strategies." *Medicinal Chemistry*, Gordon Research Conferences, Colby-Sawyer College, New London, NH.
- 2001 "Strategic Approaches for the Treatment of Alzheimer's Disease." Lecture series in Medicinal Chemistry, Associated Colleges of the Chicago Area (ACCA), Morton Arboretum, Lisle, IL.
- 2004 "Alzheimer's Disease And Emerging New Disease-Modifying Therapeutic Strategies." The 2004 Robert S. Rozman Memorial Symposium, Delaware Valley Drug Metabolism Discussion Group, Langhorne, PA.
- 2005 "Anti-Amyloid Approaches for the Treatment of Alzheimer's Disease." 7<sup>TH</sup> International Neurodegeneration In Alzheimer's Disease, Parkinson's Disease and Related Disorders, Strategic Research Institute, Princeton, NJ. (April 2005)
- 2005 "Alzheimer's Disease: The Next Generation of Symptomatic and Disease Modifying Therapies." Bio2005, Philadelphia, PA. (June 2005)
- 2005 "Disease-Modifying Therapeutic Approaches for the Treatment of Alzheimer's Disease." Therapeutic Strategies Against Neurodegenerative Conditions, Boston, MA. (Oct. 2005)

Professional Membership, Review Committees and Appointments:

- 1991-present Society for Neuroscience  
Chicago, Il
- 1993-present AD HOC Review Committee Member  
Alzheimer's Disease Center Cores (ADCCs)  
National Institute on Aging (NIA/NIH), Bethesda, Md.
- 1994-present External Peer Review Committee Member  
UMDNJ and Allied Health Services Foundation  
University of Medicine and Dentistry-New Jersey Medical School, New Brunswick, NJ.
- 1995-present Adjunct Associate Professor (Lecturer in Neurobiology and Neurotoxicology; Graduate Student Thesis Committee Member)  
New York University School of Medicine, NYU Medical Center, NY, NY.
- 1997-present Review Board Committee Member,  
Medical and Scientific Advisory Council,  
Alzheimer's Association, Inc., Chicago, Il,
- 2003-Present *Current Alzheimer Research*, Editorial Board (Bentham Press)

Bibliography:

## Publications:

1. Bystryn, J.-C., Jacobsen, J.S., Liu, P. and Heaney-Kieras, J. (1982). Comparison of cell-surface human melanoma-associated antigens identified by rabbit and murine antibodies. *Hybridoma*, 1, 465-472.
2. Refolo, L.M., Conley, M.P., Sambamurti, K., Jacobsen, J.S. and Humayun, M.Z. (1985). Sequence context effects in DNA replication blocks induced by aflatoxin B1. *Proceedings of the National Academy of Sciences, USA*, 82, 3096-3100.
3. Bystryn, J.-C., Jacobsen, J.S., Harris, M., Roses, D., Speyer, J. and Levin, M. (1986). Preparation and characterization of a polyvalent human melanoma antigen vaccine. *Journal of Biological Response Modification*, 5, 211-224.
4. Jacobsen, J.S. and Humayun, M.Z. (1986). Chloroperbenzoic acid induced DNA damage and peracid activation of aflatoxin B1. *Carcinogenesis*, 3, 491-493.
5. Jacobsen, J.S., Refolo, L.M., Conley, M.P., Sambamurti, K., and Humayun, M.Z. (1987). DNA replication-blocking properties of adducts formed by aflatoxin B1-2,3-dichloride and aflatoxin B1-2,3-oxide. *Mutation Research*, 179, 89-101.
6. Sambamurti, K., Callahan, J., Luo, X., Perkins, C.P., Jacobsen, J.S. and Humayun, M.Z. (1988). Mechanisms of mutagenesis by a bulky DNA lesion at the guanine-N7 position. *Genetics*, 120, 863-873.
7. Jacobsen, J.S., Perkins, C.P., Callahan, J.T., Sambamurti, K. and Humayun, M.Z. (1989). Mechanisms of mutagenesis by chloroacetaldehyde. *Genetics*, 121, 213-222.
8. Goldgaber, D., Harris, H.W., Hla, T., Maciag, T., Donnelly, R.J., Jacobsen, J.S., Vitek, M.P. and Gajdusek, D.C. (1989). Interleukin-1 regulates synthesis of amyloid  $\beta$ -protein precursor mRNA in human endothelial cells. *Proceedings of the National Academy of Sciences, USA*, 86, 7606-7610.
9. Jacobsen, J.S. and Humayun, M.Z. (1990). Mechanisms of mutagenesis by the vinyl chloride metabolite chloroacetaldehyde. *Biochemistry*, 29, 496-504.
10. Jacobsen, J.S., Blume, A.J. and Vitek, M.P. (1991). Quantitative measurement of alternatively spliced amyloid precursor protein mRNA expression in Alzheimer's disease and normal brain by S<sub>1</sub> nuclease protection analysis. *Neurobiology of Aging*, 12, 585-592.
11. Jacobsen, J.S., Muenkel, H.A., Blume, A.J. and Vitek, M.P. (1991). A novel species



- specific RNA related to alternatively spliced amyloid precursor protein mRNAs. *Neurobiology of Aging*, 12, 575-583.
12. Sahasrabudhe, S.R., Spruyt, M.A., Muenkel, H.A., Blume, A.J., Vitek, M.P. and Jacobsen, J.S. (1992). Release of amino-terminal fragments from Amyloid Precursor Protein reporter and mutated derivatives in cultured cells. *Journal of Biological Chemistry*, 267, 25602-25608.
  13. Sahasrabudhe, S.R., Brown, A.M., Hulmes, J., Jacobsen, J.S., Vitek, M.P., Blume, A.J., and Sonnenberg, J.L. (1993) Enzymatic generation of the amino-terminus of the  $\beta$ -amyloid peptide. *Journal of Biological Chemistry*, 268, 16699-16705.
  14. Brown, A.M., George, S., Blume, A.J., Dushin, R.G., Jacobsen, J.S. and Sonnenberg-Reines, J. (1994). Biotinylated and cysteine modified peptides as useful reagents for studying the inhibition of cathepsin G. *Analytical Biochemistry*, 217, 139-147.
  15. Jacobsen, J.S., Spruyt, M.A., Brown, A.M., Sahasrabudhe, S.R., Blume, A.J., Vitek, M.P., Muenkel, H.A. and Sonnenberg-Reines, J. (1994). The release of Alzheimer's disease  $\beta$ -amyloid peptide is reduced by phorbol treatment, *Journal of Biological Chemistry*, 269, 8376-8382.
  16. Brown, A.M., Tummolo, D.M., Spruyt, M.A., Jacobsen, J.S. and Sonnenberg-Reines, J.L. (1996). Evaluation of Cathepsins D, G, and E.C. 3.4.24.15 as candidate beta-secretase proteases using peptide and amyloid precursor protein substrates. *Journal of Neurochemistry*, 66, 2436-2445.
  17. Alpin, A.E., Gibb, G.M., Jacobsen, J.S., Gallo, J.-M. and Anderton, B.H. (1996) *In vitro* phosphorylation of the cytoplasmic domain of the amyloid precursor protein by tau proline-directed kinases. *Journal of Neurochemistry*, 67, 699-707.
  18. Alpin, A.E., Jacobsen, J.S., Anderton, B.H. and Gallo, J.-M. (1997). Effect of increased Glycogen Synthase Kinase-3 activity upon the maturation of the Amyloid Precursor Protein in cultured cells. *NeuroReport*, 8, 639-643.
  19. Brown, A.M., Tummolo, D.M., Rhodes, K.J., Hoffman, J.J., Jacobsen, J.S., and Sonnenberg-Reines, J.L. (1997). Selective aggregation of endogenous  $\beta$ -Amyloid Peptide and soluble Amyloid Precursor Protein in cerebrospinal fluid by zinc. *Journal of Neurochemistry*, 69, 1204-1212.
  20. Johnsingh, A.A., Johnston, J.M., Merz, G., Xu, J., Kotula, L., Jacobsen, J.S., and Tezapsidis, N. (2000). Altered Binding of Mutated Presenilin with Cytoskeleton-Interacting Proteins. *FEBS Letters*, 465, 53-58.
  21. Kajkowski, E.M., Lo, C.F., Ning, X., Walker, S., Sofia, H., Wang, W., Edris, W.,



- Chandra, P., Wagner, E., Vile, S., Ryan, K., McHenry-Rinde, B., Smith, S.C., Wood, A., Rhodes, K.J., Kennedy, J., Bard, J., Jacobsen, J. S. and Ozenberger, B.A. (2001).  $\beta$ -Amyloid Peptide-Induced Apoptosis Regulated by a Novel Protein Containing a G Protein Activation Module. *Journal of Biological Chemistry*, 276, 18748-18756.
22. Jacobsen, J. S. (2002). Alzheimer's Disease: An Overview of Current and Emerging Therapeutic Strategies. *Current Topics in Medicinal Chemistry*, 2, 343-352.
  23. Naureckiene, S., Ma, L., Sreekumar, K., Purandare, U., Frederick, C., Lo, C.F., Huang, Y., Chiang, L.W., Grenier, J.M., Ozenberger, B.A., Jacobsen, J.S., Kennedy J.D., DiStefano, P.S., Wood, A., Bingham, B. (2003). Functional Characterization of Narc 1; A Novel Proteinase Related to Proteinase K. *Archives of Biochemistry and Biophysics*, 420, 55-67.
  24. Zhang, M.-Y., Kerns, E., McConnell, O., Sonnenberg-Reines, J., Zaleska, M.M., Jacobsen, J.S., Butera, J. and Kreft, A. (2004). "Brain and plasma exposure profiling in early drug discovery using cassette administration and fast liquid chromatography-tandem mass spectrometry." *Journal of Pharmaceutical and Biomedical Analysis*, 34, 359-368.
  25. Liu, F., Lo, C.F., Ning, X.-P., Kajkowski, E.M., Jin, M., Chiriac, C., Gonzales, C., Naureckiene, S., Lock, Y.-W., Pong, K., Zaleska, M.M., Jacobsen, J.S., Silverman, S. and Ozenberger, B.A. (2004). Expression of NALP1 in Cerebellar Granule Neurons Stimulates Apoptosis. *Cellular Signalling*, 16, 1013-1021.
  26. Gundersen, E., Fan, K., Haas, K., Huryn, D., Jacobsen, J.S., Kreft, A., Martone, R., Mayer, S., Sonnenberg-Reines, J., Sun, S.-C., Zhou, H. (2005). Molecular-Modeling Based Design, Synthesis, and Activity of Substituted Piperidines as  $\gamma$ -Secretase Inhibitors. *Bioorganic and Medicinal Chemistry Letters*, 15, 1891-1894.
  27. Pangalos, M.N., Jacobsen, J.S. and Reinhart, P.H. Disease Modifying Strategies for the Treatment of Alzheimer's Disease Targeted at Modulating Levels of the  $\beta$ -Amyloid Peptide. (2005). *Biochemical Society Transactions*. 33, 553-558.
  28. Jacobsen, J.S., Reinhart, P.H. and Pangalos, M.N. (2005). Current Concepts in Therapeutic Strategies Targeting Cognitive Decline and Disease Modification in Alzheimer's Disease. *NeuroRx*, 2, 612-626.
  29. Comery, T.A., Martone, R.L., Aschmies, S., Atchison, K.P., Diamantidis, G., Gong, X., Zhou, H., Pangalos, M.N., Sonnenberg-Reines, J., Kreft, A.F., Jacobsen, J.S. and Marquis, K.L. (2005). Acute  $\gamma$ -Secretase Inhibition Improved Contextual Fear Conditioning in the Tg2576 Mouse Model of Alzheimer's Disease. *Journal of Neuroscience*. 25, 8898-8902.

30. Lo, C.F., Ning, X., Jin, M., Kajkowski, E.M., Liu, F., Gonzales, C., Zaleska, M.M., Wang, W., Betty-Blacher, M., Franco, R., Wood, A., Jacobsen, J.S., Silverman, S. and Ozenberger, B.A. (2005). Induced Expression of Death Domain Genes NALP1 and NALP5 Following Neuronal Injury (Submitted, *Journal of Molecular Neuroscience*).
31. Bingham, B., Shen, R., Kotnis, S., Lo, C.F., Ozenberger, B.A., Ghosh, N., Kennedy, J.D., Jacobsen, J.S., Grenier, J.M., DiStefano, P.S., Chiang, L.W. and Wood, A. (2005). Pro-apoptotic effects of NARC 1 (=PCSK9), the gene encoding a novel serine proteinase (Submitted for internal approval).
32. Jacobsen, J.S., Wu, C.-C., Redwine, J.M., Comery, T.A., Arias, R., Bowlby, M., Martone, R., Morrison, J.H., Reinhart, P.H., Pangalos, M.N. and Bloom, F.E. Early Behavioral and Synaptic Deficits Detected in a Mouse Model of Alzheimer's Disease (Manuscript in preparation).

#### Book Chapters:

1. Donnelly, R.J., Jacobsen, J.S., Rasool, C.G., Bartus, R., Blume, A.J. and Vitek, M.P. (1989) Isolation and expression of multiple forms of beta amyloid protein precursor cDNA in Alzheimer's Disease. In: *Alzheimer's Disease and Related Disorders. Progress in Clinical and Biological Research, Volume 317*. K. Iqbal, H.M. Wisniewski and B. Winblad (editors), Alan R. Liss, Inc., New York. pp. 925-937.

#### Abstracts:

1. Jacobsen, J.S. and Keller, J.R. 1980. Proline production of *Agrobacterium rubi* strains as a major contributing factor in the growth enhancement of *Thielaviopsis basicola*. *Abstracts of the Annual Meeting, American Society for Microbiology*, Miami Beach, Florida, 11-16 May, 1980.
2. Refolo, L.M., Conley, M.P., Sambamurti, K., Jacobsen, J.S., and Humayun, M.Z. 1985. Sequence context effects in DNA replication blocks induced by aflatoxin B1. *Abstracts of the 13th International Congress of Biochemistry*, Amsterdam, The Netherlands, 25-30 August, 1985.
3. Refolo, L.M., Conley, M.P., Sambamurti, K., Jacobsen, J.S., and Humayun, M.Z. 1985. Sequence context effects in DNA replication blocks induced by aflatoxin B1. *Abstracts of the Mechanism of Mutagenesis: Impact on Carcinogenesis*, Mittelwihr, France, 22-27 September, 1985.
4. Jacobsen, J.S., Refolo, L.M., Sambamurti, K. and Humayun, M.Z. 1986. Replication blocks induced by aflatoxin B1: DNA sequence and conformation specificity and

- effect of manganese. UCLA Symposia on Molecular and Cellular Biology: Mechanisms of DNA Replication and Recombination, *Journal of Cellular Biochemistry, Supplement 10B*, Park City, Utah, 22 February-23 March, 1986.
5. Jacobsen, J.S. and Humayun, M.Z. 1986. Chloroacetaldehyde-induced DNA lesions block DNA replication and permit misincorporation at A and C residues. *Abstracts of the annual meeting of the Environmental Mutagen Society*, Washington, D.C., 21-23 April, 1986.
6. Jacobsen, J.S. and Humayun, M.Z. 1986. Effect of chloroacetaldehyde-induced lesions on DNA template activity. New Jersey State Commission on Cancer Research: *A Workshop on Cancer Research in New Jersey*, Woodbridge, New Jersey, 22 November, 1986.
7. Sambamurti, K., Callahan, J.T., Perkins, C.P., Jacobsen, J.S. and Humayun, M.Z. 1988. Activated aflatoxin induces transversions and transitions with equal efficiencies in phage M13. UCLA Symposia on Molecular and Cellular Biology: Mechanisms and Consequences of DNA Damage Processing. *Journal of Cellular Biochemistry, Supplement 12A*, Taos, New Mexico, 24-31 January, 1988.
8. Donnelly, R.J., Jacobsen, J.S., Rasool, C.G., Bartus, R., Blume, A.J. and Vitek, M.P. 1988. Isolation and expression of multiple forms of beta amyloid protein precursor cDNA in Alzheimer's Disease. *Abstracts of Proceedings of the First International Conference on Alzheimer's Disease and Related Disorders*. Las Vegas, Nevada, September, 1988.
9. Vitek, M.P., Jacobsen, J.S., Donnelly, R.J. and Blume, A.J. 1989. Quantitative and qualitative analysis of multiple APP RNA forms in normal and Alzheimer's Brains. UCLA Symposia on Molecular and Cellular Biology: Molecular Biology of Aging. *Journal of Cellular Biochemistry, Supplement 13C*, p. 166, Santa Fe, New Mexico, 4-10 March, 1989.
10. Jacobsen, J.S., Donnelly, R.J., Blume, A.J. and Vitek, M.P. 1989. Quantitative and qualitative analysis of multiple APP RNA forms in normal and Alzheimer's Brains. *Abstracts of Molecular and Cellular Mechanisms of Neuronal Plasticity in Aging and Alzheimer's Disease*, p. 43. National Institute on Aging, The National Institutes of Health, Bethesda, Maryland, 1-3 May, 1989.
11. Jacobsen, J.S., Donnelly, R.J., Beer, B., Blume, A.J. and Vitek, M.P. 1989. Quantitative and qualitative characterization of multiple APP RNA forms in normal and Alzheimer's brains by S1 protection analysis. *Society for Neuroscience Abstracts*, vol. 15, p. 647. Phoenix, Arizona, 29 October-3 November, 1989.
12. Jacobsen, J.S., Blume, A.J. and Vitek, M.P. 1990. A major amyloid RNA in human

- brain is species specific and may encode a novel soluble protein. UCLA Symposia on Molecular and Cellular Biology: Molecular Neurobiology. *Journal of Cellular Biochemistry, Supplement 14F*, p. 59, South Padre Island, Texas, 17-23 April, 1990.
13. Jacobsen, J.S., Beer, B., Blume, A.J. and Vitek, M.P. 1990. A specific increase in APP-695 mRNA levels is correlated with amyloid plaque pathology in the cerebral cortex of Alzheimer's disease. *Society for Neuroscience Abstracts*, vol. 16, p. 345. St. Louis, Missouri, 28 October-2 November, 1990.
  14. Vitek, M.P., Jacobsen, J.S., Sonnenberg, J., Sahasrabudhe, S., Muenkel, H.A., Spruyt, M.A., and Blume, A.J. 1991. The APPREP System, Protein Processing and BAP Production: Characterization of APP-Reporter Protein. *Society for Neuroscience Abstracts*, vol. 17, p. 1443. New Orleans, Louisiana, 10-15 November, 1991.
  15. Sonnenberg, J.L., Sahasrabudhe, S.R., Hulmes, Jacobsen, J.S., Blume, A.J. and Vitek, M.P. 1992. N-terminal cleavage of  $\beta$ -amyloid by Cathepsin G is dependent on pH and ionic conditions. *Society for Neuroscience Abstracts*, vol. 18, p. 1441. Anaheim, California, 25-30 October, 1992.
  16. Sahasrabudhe, S.R., Spruyt, M.A., Muenkel, H.A., Blume, A.J., Vitek, M.P. and Jacobsen, J.S. 1992. Expression of amyloid precursor protein and its derivative in cultured cells: Lack of sequence specificity in cleavage of APP by secretase. *Society for Neuroscience Abstracts*, vol. 18, p. 19. Anaheim, California, 25-30 October, 1992.
  17. Sonnenberg-Reines, J.L., Brown, A.M., George, S., Blume, A.J., Jacobsen, J.S. and Barrett, J.E. 1993. Biotinylated and cysteine modified peptides as useful reagents for studying the inhibition of putative N-terminal  $\beta$ -amyloid peptide enzymes. *Society for Neuroscience Abstracts*, vol. 19, p. 861. Washington, D.C., 7-11 November, 1993.
  18. Jacobsen, J.S., Spruyt, M.A., Sonnenberg, J.L., Blume, A.J., Brown, A.M. and Muenkel, H.A. 1993. Phorbol-induced cleavage of amyloid precursor protein occurs independently of its phosphorylation and reduces the formation of beta amyloid peptide. *Society for Neuroscience Abstracts*, vol. 19, p. 18. Washington, D.C., 7-11 November, 1993.
  19. Sonnenberg-Reines, J.L., Brown, A.M., Tummolo, D.M., Spruyt, M.A. and Jacobsen, J.S. 1994. Comparison of a brain-purified metalloprotease with human cathepsin G: Evaluation of sequence specificity using peptide substrates and regional selectivity using purified brain APP. *Society for Neuroscience Abstracts*, vol. 20, p. 1484. Miami, Fl., 13-18 November, 1994.
  20. Brown, A.M., Jacobsen, J.S., Spruyt, M.A., Tummolo, D.M. and Sonnenberg-Reines, J.L. 1994. Sequencing of a C-terminal fragment of APP defines the site of cleavage

- at the carboxy-terminus of BAP. *Society for Neuroscience Abstracts*, vol. 20, p. 439. Miami, FL, 13-18 November, 1994.
21. Brown, A.M., Tummolo, D.M., Hoffman, J., Jacobsen, J.S. and Sonnenberg-Reines, J.L. 1995. Zinc induces aggregation of PN2 and  $\beta$ AP in Dog, Monkey and Human cerebrospinal fluid. *Society for Neuroscience Abstracts*, vol. 21, p. 1281. San Diego, Ca., 11-16 November, 1995.
  22. Tummolo, D.M., Brown, A.M., Jacobsen, J.S., Rhodes, K. and Sonnenberg-Reines, J.L. 1995.  $\beta$ AP levels decrease in the CSF following cholinergic lesioning of the fimbria fornix. *Society for Neuroscience Abstracts*, vol. 21, p. 1480. San Diego, Ca., 11-16 November, 1995.
  23. Jacobsen, J.S. 1996. Therapeutic Strategies to Reduce Formation of  $\beta$ -amyloid peptide in Alzheimer's Disease. *Therapeutic Opportunities in Alzheimer's Disease: Advances in Diagnostics and Drug Development*. International Business Communications, U.S.A., Oak Brook, Illinois. 17-18 June, 1996.
  24. Anderton, B.H., Aplin, A.E., Bayley, P.M., Brion, J.-P., Davis, D.R., Gallo, J.-M., Gibb, G.M., Hanger, D.P., Jacobsen, J.S., Lovestone, S., Reynolds, C.H., Utton, A. and Vandecastelaere, A. 1996. Glycogen synthetase kinase-3 and the phosphorylation of tau and APP. *Research on Age-Related Phenomena, Neurodegeneration and Neuropathology: Abstracts of the Fifth International Conference on Alzheimer's Disease and Related Disorders*. *Neurobiology of Aging*, supplement 17, number 4S, p. s76. Osaka, Japan, 24-29 July, 1996.
  25. Tummolo, D.M., Sun, S.C., Xiang, Q., Zhou, H., Jacobsen, J.S., and Sonnenberg-Reines, J.L. 1996. Quantification of Alzheimer's  $\beta$ -amyloid peptide levels in the plasma, CSF and brain tissue from guinea pig following administration of classical protease inhibitors. *Society for Neuroscience Abstracts*, vol. 22, p. 1170. Washington, DC., 16-21 November, 1996.
  26. Sun, S.C., Aschmies, S., Jacobsen, J. S., Welmaker, G., Lombardo, L., Moyer, J., and Sonnenberg-Reines, J. 1997. Measurement of Alzheimer's  $\beta$ -amyloid peptide ( $\beta$ -AP) levels in the plasma, CSF and brain tissue from guinea pigs following administration of compounds found inhibitor in the cellular  $\beta$ -AP assay. *Society for Neuroscience Abstracts*, vol. 23, p. 535. New Orleans, Louisiana, 25-30 October, 1997.
  27. Krishnamurthy, K., Gong, E., Ellestadt, G., Tasse, R., Fairman, D., Lu, P., Boast, C., and Jacobsen, J.S. Characterization of Fibrillogenesis of Amyloid Peptide. 215<sup>th</sup> National Meeting and Exposition for the American Chemical Society Annual Meeting, p. 101, Dallas, Texas, March 29-April 2, 1998.
  28. Tezapsidis, N., Johnsingh, A., Li, H.-C., Efthimiopoulos, S., Elder, G. A., Jacobsen,



- J. S., Wang, R., Kreis, T. E., Robakis, N. K. 1998. Presenilin-1 is associated with CLIP-170, a microtubule-Interacting Protein. *Research on Age-Related Phenomena, Neurodegeneration and Neuropathology: Abstracts of the Sixth International Conference on Alzheimer's Disease and Related Disorders. Neurobiology of Aging*, Volume 19, number 4S, p. s301. Amsterdam, 18-23 July, 1998.
29. Tezapsidis, N., Johnsingh, A., Li, H.-C., Efthimiopoulos, S., Jacobsen, J. S., Kreis, T. E., Robakis, N. K. 1998. Presenilin-1 is associated with CLIP-170, a microtubule-Interacting Protein. *Society for Neuroscience Abstracts*. vol. 24, p. 758. Los Angeles, California, 7-12 November, 1998.
  30. Johnsingh, A., Kotula, L., Efthimiopoulos, S., Jacobsen, J. S., Kreis, T. E., Robakis, N. K., Tezapsidis, N. 1998. Presenilin-1 is co-localized with CLIP-170, and their interaction mediates A $\beta$  production. *Society for Neuroscience Abstracts*. vol. 24, p. 468. Los Angeles, California, 7-12 November, 1998.
  31. Jacobsen, J. S., Tezapsidis, N., Johnsingh, A., Kotula, L., and Kreis, T. E. 1999. Presenilin-1 mediates A $\beta$  production through its binding to a microtubule-associated protein. *Keystone Symposia on Molecular and Cellular Biology: Molecular Mechanisms in Alzheimer's Disease. Abstract Supplement*, p. 42, Taos, New Mexico, 3-8 March, 1999.
  32. Ozenberger, B. A., Kajkowski, E., Lo, F., Walker, S., Sofia, H., Rhodes, K., Bard, J., and Jacobsen, J. S., 1999. A novel protein containing a potential G protein coupling module affects cellular sensitivity to  $\beta$ -amyloid peptide. *Keystone Symposia on Molecular and Cellular Biology: Molecular Mechanisms in Alzheimer's Disease. Abstract Supplement*, p. 54, Taos, New Mexico, 3-8 March, 1999.
  33. Kajkowski, E., Lo, F., Smith, S., Walker, S., Wood, A., Sofia, H., Bard, J., Jacobsen, J. S. and Ozenberger, B. A. 1999. A novel family of apoptosis modulators containing G protein coupling motif. *Annual Meeting of the American Society for Biochemistry and Molecular Biology. Abstract Supplement*, San Francisco, CA, 16-20 May, 1999.
  34. Lo, C. F., Kajkowski, E. M., Walker, S., Smith, S. C., Wood, A., Finley, J., Rhodes, K., Bard, J., Jacobsen, J. S., and Ozenberger, B. A. 1999. The A $\beta$  binding protein  $\beta$ BP1 is a member of a family of structurally novel apoptosis modulators. *Society for Neuroscience Abstracts*. vol. 29, p. 206. Miami, FL., 23-28 October, 1999.
  35. Ozenberger, B. A., Lo, C. F., Kajkowski, E. M., Walker, S., Smith, S. C., Wood, A., Bard, J., and Jacobsen, J. S. 1999.  $\beta$ BP1 mediates cellular vulnerability to A $\beta$  by a G protein and caspase-dependent mechanism. *Society for Neuroscience Abstracts*. vol. 29, p. 291. Miami, FL., 23-28 October, 1999.
  36. Tezapsidis, N., Johnston, J. M., Merz, G. S., Jacobsen, J. S., Xu, J., Kotula, L.,

- Sapienza, V. J., and Johnsingh, A. A. 2000. Presenilin's action on Amyloid Precursor Protein cleavage is mediated through cytoplasmic linker protein 170. *World Alzheimer's Congress 2000: Pivotal Research. Abstract Supplement*, #818, p. 82, Washington, D.C., 9-13 July, 2000.
37. Wang, W., Kajkowski, E., Lo, F.L., Jacobsen, J.S., and Ozenberger, B. 2000. A $\beta$  Binding Protein BBP1 and Structurally Related Proteins Can Physically Associate with APP. *Society for Neuroscience Abstracts*. vol. 30, p. 436. New Orleans, LA, 4-9 November, 2000.
  38. Ning, X., Kajkowski, E., Ryan, K., Edris, W., Chandra, P., Vile, S., Walker, S., Bard, J., Jacobsen, J.S., Kennedy, J. and Ozenberger, B. 2000. A $\beta$  Binding Protein BBP1 shows selective and high affinity association with A $\beta$  binding peptide *in vitro*. *Society for Neuroscience Abstracts*. vol. 30, p. 436. New Orleans, LA, 4-9 November, 2000.
  39. Walker, S.G., Ryan, K., Vile, S., Ning, X., Edris, W., Chandra, P., Jacobsen, J.S., Kennedy, J., Ozenberger, B. and Bard, J. 2000. Beta-Amyloid Binding Protein BBP1 Specifically binds A $\beta$  1-40 *in vitro*. *Society for Neuroscience Abstracts*. vol. 30, p. 436. New Orleans, LA, 4-9 November, 2000.
  40. Ozenberger, B., Lo, F.L., Wang, W., Kajkowski, E., Walker, S., Bard, J., Smith, S.C., Wood, A., Rinde, B., Kennedy, J., and Jacobsen, J.S. 2000. A $\beta$ -Induced Apoptosis in Cultured Neurons is Regulated by the BBP1 Protein. *Society for Neuroscience Abstracts*. vol. 30, p. 155. New Orleans, LA, 4-9 November, 2000.
  41. Zhang, M.-Y., Kerns, E., Sonnenberg-Reines, J., Ashmies, S., Jacobsen, J.S., Cai, Y., McConnell, O. Brain and plasma exposure profile in drug discovery by cassette administration. *49th American Society for Mass Spectrometry Conference, Chicago, IL, May 87-31, 2001*.
  42. Zhang, M.-Y., Kerns, E., Cai, Y., McConnell, O., Sonnenberg-Reines, J., Zaleska, M., Aschmies, S., Bramlett, D., Jacobsen, J.S., Butera, J., and Kreft, A. 2001. Brain and Plasma Exposure Profile in Drug Discovery by Cassette Administration and Liquid Chromatography/Tandem Mass Spectrometry. *49th Conference on Mass Spectrometry and Allied Topics, Chicago, IL, 28-31 May, 2001*.
  43. Martone, R., Atchison, K., Gong, X., Kreft, A., Diamantidis, G., Aschimes, S., Sonnenberg-Reines, J., Sun, R., and Jacobsen, J.S. A method for the *in vivo* assessment of APP gamma-secretase inhibitors using quantitative extraction and measurement of APP-derived Ct-99 fragment. *Strategic Research Institute, Princeton, NJ, 25-27 July, 2001*.

44. Jin, M., Turner, J., Chiriac, C., Jacobsen, J.S., Kirsch, D.R., Bard, J., and Silverman, S.J. 2001.  $\gamma$ -Secretase Gene Hunt: A Generalizable Activator-release Screen for Proteases and Protease Inhibitors. *Society for Neuroscience Abstracts*. vol. 31, p. 98. San Diego, CA, 10-15 November, 2001.
45. Comery, T.A., Sonnenberg-Reines, J., Kreft, A.F., Diamantidis, G., Jacobsen, J.S., and Marquis, K.L. Reversal of hippocampal cognitive impairment in the Tg2576 mouse model of Alzheimer's Disease. *6th International Conference on Alzheimer's and Parkinson's Disease*, Seville, Spain, May 8-12, 2002.
46. Ning, X., Jin, M., Kajkowski, E., Lo, C.F., Gonzales, C., Zaleska, M.M., Franco, R., Jacobsen, J.S., Silverman, S., and Ozenberger, B.A. Caspase Recruitment Domain Gene Expression Analysis in Model Systems of Neurodegeneration. Program No. 198.3. 2002 *Abstract Viewer/Itinerary Planner*. Washington, DC: Society for Neuroscience, Orlando, FL. 2-7 November, 2002. Online.
47. Stein, A.P., Hu, Y., Bard, J., Gong, X., Jacobsen, J.S., and Boast, C.A. Rat Brain Expression of Mutated hAPP and Processing to A $\beta$  After Gene Transduction with Adenovirus Vector. Program No. 296.11. 2002 *Abstract Viewer/Itinerary Planner*. Washington, DC: Society for Neuroscience, Orlando, FL. 2-7 November, 2002. Online.
48. Shen, R., Kotnis, S., Ma, L., Sreekumar, K., Lo, C.F., Naureckiene, S., Jenkins, L.P., Ozenberger, B.A., Jacobsen, J.S., Kennedy, J.D., Wood, A., and Bingham, B. Mutational analysis of NARC1, a novel target in neuronal apoptosis, using laser scanning cytometry. *Experimental Biology (ASPET)*, San Diego, CA, 11-15 April, 2003.
49. Mayer, S.C., Aschmies, S., Atchison, K., Chlenov, M., Comery, T.A., Gallaway, W., Gong, G., Hoke, M. E., Jacobsen, J.S., Jain, U., Kreft, A.F., Lu, P., Martone, R., Oganessian, A., Sangari, R., Sonnenberg-Reines, J., Sun, R. and Zhou, H. The Design and Synthesis of WAY-210953 – A "Notch-Separable"  $\gamma$ -Secretase Inhibitor Pre-Development Lead for the Treatment of Alzheimer's Disease (Wyeth Retreat, 7 May, 2003, Princeton, N.J.).
50. Naureckiene, S., Ma, L., Sreekumar, K., Lo, C.F., Huang, Y., Ozenberger, B.A., Jacobsen, J.S., Kennedy, J.D., Wood, A. and Bingham, B. Characterization of NARC 1, A Novel Gene in Neuronal Apoptosis *6th IBRO World Congress of Neuroscience, Prague, Czech Republic, July 10-15, 2003*.
51. Ma, L., Kotnis, S., Shen, R., Naureckiene, S., Lo, C.F., Jenkins, L.P., Sreekumar, K., Huang, Y., Ozenberger, B.A., Jacobsen, J.S., Kennedy, J.D., Wood, A., Bingham, B. Functional Characterization of NARC 1, A Novel Gene in Neuronal Apoptosis. *19th International Congress of Biochemistry and Molecular Biology, Toronto, Canada, July 20-24, 2003*.
52. Ma, L., Kotnis, S., Shen, R., Naureckiene, S., Lo, C.F., Jenkins, L.P., Sreekumar, K., Huang, Y., Ozenberger, B.A., Jacobsen, J.S., Kennedy, J.D., Wood, A., Bingham, B. Functional Characterization of NARC 1, A Novel Gene in Neuronal Apoptosis. *6th World Congress on Inflammation, Vancouver, Canada, August 2-6, 2003*.



53. Comery, T., Aschmies, A., Atchison, K.P., Borusovic, K., Diamantidis, G., Gong, X., Mayer, S.C., Zhou, H., Martone, R.L., Sonnenberg-Reines, J., Kreft, A.F., Jacobsen, J.S., and Marquis, L.K. Acute gamma-Secretase Inhibition Improves Cognition in the Tg2576 Mouse Model of Alzheimer's Disease. *2003 Abstract Viewer/Itinerary Planner*. Washington, DC: Society for Neuroscience, New Orleans, LA. 8-12 November, 2003.
54. Liu, F., Ning, X., Jin, M., Lo, C.F., Kajkowski, E., Chiriac, C., Naureckiene, S., Lock, T., Pong, K., Gonzales, C., Zaleska, M.M., Jacobsen, J.S., Silverman, S., Ozenberger, B.A. Death domain protein NALP1 binds dATP and regulates neuronal apoptosis. *2003 Abstract Viewer/Itinerary Planner*. Washington, DC: Society for Neuroscience, New Orleans, LA. 8-12 November, 2003. Online.
55. Wagner, E., Comery, T., Turner, J., Hu, Y., Aschmies, S., Oganessian, A., Gonzales, C., Erdei, J., Gunawan, I., Fobare, W., Solvibile, W., Quagliato, D., Andre, P., Zhou, P., Yan, Y., Barnes, K., Johnson, M., Klos, A., Hui, Y., Cowling, R., Jin, G., Lin, L., Strand, J., Di, L., Chlenov, M., Kraml, C., Jain, U., Polakowski, S., Huselton, C., Fan, K., Chopra, R., Jacobsen, J.S., Robichaud, A., Magolda, R., Pangalos, M., Malamas, M., and Bard, J. A Small Molecule BACE1 Inhibitor Lowers Brain Abeta Levels And Reverses Cognitive Deficits in a Transgenic Mouse Model of Alzheimer's Disease. (Wyeth Retreat, 3 May, 2004, Princeton, N.J.).
56. Comery, T.A., Marquis, K.L., Seubert, P., Zaleska, M.M., Jacobsen, J.S. Acute passive immunization against  $\beta$ -amyloid improves cognition in a transgenic mouse overexpressing hAPP. 9th International Conference of Alzheimer's Disease and Related Disorders, Philadelphia, PA, 17-22 July 2004.
57. Comery, T.A., Marquis, K.L., Pangalos, M.N., Jacobsen, J.S., and Zaleska, M.M. Hippocampal cognitive dysfunction in the Tg2576 mouse model of Alzheimer's Disease. *2004 Abstract Viewer/Itinerary Planner*. Washington, DC: Society for Neuroscience, San Diego, CA. 23-27 October, 2004. Online.
58. Pangalos, M.N., Reinhart, P. and Jacobsen, J.S. Disease modifying therapies for the treatment of Alzheimer's disease targeted at modulating levels of the amyloid  $\beta$ -peptide. Molecular Mechanisms of Neurodegeneration: a Joint Biochemical Society/Neuroscience Ireland Focused Meeting. Biochemical Society. Dublin, Ireland. 14-16 March, 2005.
59. Kubek, K., Atchison, K., Pong, K., Graziani, E., Jacobsen, J.S., Reinhart, P.H., Pangalos, M.N., and Martone, R. Rotenone-induced aggregation of  $\alpha$ -synuclein is reversed by rapamycin. International Society for Neurochemistry, European Society for Neurochemistry Meeting, Innsbruck, Austria, 21 August, 2005.
60. Fan, K.Y., Huang, X., Aulabaugh, A., Gundersen, E., Haas, K., Harrison, B., Jacobsen, J.S., Katz, A.H., Kreft, A., Martone, R., Mayer, S., Porte, A. Pharmacophore Hypothesis for  $\gamma$ -Secretase Inhibitor and Application in Virtual Screening. 230<sup>th</sup> American Chemical Society (ACS) National Meeting and Exposition, Washington, DC, 28 August-1 September, 2005.

61. Pangalos, MP., Jacobsen, J.S., Comery, T.A., Wu, C.-C., Redwine, J.M., Arias, R., Martone, R., Aschmies, S., Atchinson, K.P., Morrison, J.H., Marquis, K., Bloom, F.E., Reinhart, P.H. Early-onset Behavioral and Synaptic Deficits in a Mouse Model of Alzheimer's Disease Are Reversed by Inhibition of Gamma Secretase. 2005 ACNP.
62. Lo, C.F., Ning, X., Gonzales, C., Liu, F., Kajkowski, E.M., Zaleska, M.M., Wood, Jacobsen, J.S., and Ozenberger, B.A. Induced expression of a pro-apoptotic gene NALP5 following neuronal injuries. 2005 ASCB.
63. Comery, T.A., Marquis, K.L., Barbour, R., Johnson-Wood, K., Seubert, P., Schenk, D., Pangalos, M.N., Reinhart, P.H. and Jacobsen, J.S. Passive immunization against  $\beta$ -amyloid leads to acute cognition improvement. (Submitted for Society for Neuroscience, Washington, DC, 12-16 November, 2005).
64. Jacobsen, J.S., Comery, T.C., Martone, R., Aschmies, S., Oganessian, A., Zhou, H., Atchison, K., Elokda, H., Crandall, D., Zaleska, M.M., Reinhart, P.H. and Pangalos, M.N. Small molecule inhibitors of PAI-1 activate the tPA/plasminogen cascade and enhance proteolytic clearance of A $\beta$  as a novel therapeutic strategy for the treatment of Alzheimer's Disease. (Submitted for Society for Neuroscience, Washington, DC, 12-16 November, 2005).
65. Bard, J., Turner, J., Hu, Y., Wagner, E., Aschmies, S., Jacobsen, J.S., Reinhart, P.H., Pangalos, M.N., Cowling, R., Jin, G., Lin, L., Strand, J., Stahl, M., Kriz, R., Chopra, R., Fan, K., Somers, W., Ellingboe, J., Sukhdeo, M., Jennings, L., Stock, J., Lovering, F., Condon, J., Solvibile, W., Fobare, W., Zhou, P., Manas, E., Cole, D. and Malamas, M. Identification and characterization of small molecule BACE1 inhibitors. (Submitted for Society for Neuroscience, Washington, DC, 12-16 November, 2005).
66. Ma, L., Kennedy, J.D., Lu, P., Piesla, M., Jacobsen, J.S., Rogers, K., Riddell, D. *In vitro* and *in vivo* anti-inflammatory activity of LxR agonists. (Submitted for Society for Neuroscience, Washington, DC, 12-16 November, 2005).
67. Zhou, H., Kirksey, Y., Atchison, K., Aschmies, S., Comery, T.A., Kouranova, E., Ring, R.H., Oganessian, A., Martone, R., Pangalos, M.N., Reinhart, P.H., Jacobsen, J.S. and Riddell, D.R. Liver X Receptor activation does not inhibit amyloid precursor processing in young APP transgenic mice. (Submitted for Society for Neuroscience, Washington, DC, 12-16 November, 2005).
68. Lo, C.F., Ning, X., Gonzales, C., Liu, F., Kajkowski, E.M., Zaleska, M.M., Wood, Jacobsen, J.S., and Ozenberger, B.A. Induced expression of a pro-apoptotic gene NALP5 following neuronal injuries. 2005 ASCB.